AngioDynamics, Inc. has launched the RECOVER-AV clinical trial in Europe to evaluate the effectiveness and safety of the AlphaVac Multipurpose Mechanical Aspiration F1885 System in treating acute intermediate-risk pulmonary embolism (PE). This trial follows the success of the APEX-AV trial in the U.S., which showed significant improvements in right ventricular function and clot burden reduction. The RECOVER-AV trial aims to enroll patients across 20 European hospital sites to support the adoption of AlphaVac in the European market, where the prevalence and severity of PE are higher than in the United States.
The news of the RECOVER-AV trial caused a 2.1% drop in ANGO’s stock price, closing at $7.54. However, the company’s innovative devices are highly regarded by physicians in growing healthcare markets. The advancement in the treatment of pulmonary embolism is expected to improve blood flow in the vascular system, expand cancer treatment options, and enhance patient quality of life, which could lead to a positive impact on the stock in the future.
The RECOVER-AV trial is significant for AngioDynamics as it expands their clinical research efforts in Europe, where PE prevalence is higher than in the U.S. By enrolling patients in multiple European centers, the study aims to demonstrate the effectiveness of the AlphaVac F1885 System in treating intermediate-risk PE and reducing Major Adverse Events like death or bleeding.
Patients in the RECOVER-AV trial will be monitored for 12 months, with assessments of functional outcomes at different intervals post-procedure. The trial follows the CE Mark approval of the AlphaVac F1885 System, indicating its potential to improve treatment options for PE patients in a high-need market.
According to a report in BioSpace, the pulmonary embolism market is expected to reach $3.3 billion by 2034, with a CAGR of 5.5%. The growth in PE diagnosis is driven by advancements in imaging technologies such as Computed Tomography Pulmonary Angiography and Magnetic Resonance Angiography, providing accurate and non-invasive options for patients.
In May, AngioDynamics presented results from the APEX-AV trial, demonstrating the safety and efficacy of the AlphaVac F1885 System in treating acute intermediate-risk PE patients. Despite a 3.8% decline in the stock price year to date, the company has shown favorable earnings surprises in the past quarters, with an average surprise of 28.61%.
AngioDynamics currently holds a Zacks Rank #1 (Strong Buy), indicating a positive outlook. Other top-ranked stocks in the medical space include Universal Health Services, ATI Physical Therapy, and Aveanna Healthcare. These companies have shown strong earnings performance and growth potential in their respective markets.
Overall, the initiation of the RECOVER-AV trial in Europe is a significant step for AngioDynamics in expanding their presence in the treatment of pulmonary embolism. With positive market prospects and a strong earnings track record, the company is well-positioned for future growth and success in the healthcare industry.
